Plunkett Research Online: Denali Therapeutics

DENALI THERAPEUTICS (DNLI:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

A clinical-stage biopharmaceutical company.....



Denali Therapeutics
Ticker: DNLI
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 650 866-8548
Fax:
Address: 161 Oyster Point Boulevard
South San Francisco, CA 94080 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Vaccines, Skin Replacement Products and Biologicals Manufacturing
Contacts Description

Ryan Watts CEO/Co-Founder/Director/President
Steve Krognes CFO/Chief Accounting Officer/Treasurer
See More
A clinical-stage biopharmaceutical company.....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2020 2019 2018 2017 2016 2015
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Name Title Salary (US$) Bonus (US$)
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: